Point72 Hong Kong’s Atossa Therapeutics ATOS Stock Holding History

Point72 Hong Kong’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-682	Closed	-$65K	–	1964
2021 Q2	$65K	Buy	+682	New	+$36.1K	﹤0.01%	1416

Other funds holding ATOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Hong Kong's ATOS Position: Q3 2021 in Review

Point72 Hong Kong sold out of Atossa Therapeutics (ATOS) in Q3 2021, closing a stake of 682 shares — an estimated $65K sold.

Point72 Hong Kong first reported a position in ATOS in Q2 2021 and held it in 1 quarter. The position peaked at $65K in Q2 2021. 93 funds tracked by Wall St. Rank hold ATOS as of Q3 2021.

Point72 Hong Kong reported no remaining Atossa Therapeutics position as of Q3 2021 after selling out during the quarter.
Point72 Hong Kong sold 682 Atossa Therapeutics shares in Q3 2021, an estimated $65K.
Point72 Hong Kong first reported a position in Atossa Therapeutics in Q2 2021 and held it in 1 quarter.
Point72 Hong Kong's Atossa Therapeutics position peaked at $65K in Q2 2021.
93 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.